The strongest associations with weight loss success or failure – independent of BMI – are found in the genetic capacity of the gut microbiome. These new findings open the door to diagnostic tests that can identify people likely to lose weight with healthy lifestyle changes and those who might need more drastic interventions.
Researchers from Institute for Systems Biology (ISB), Fred Hutchinson Cancer Research Center and other organizations have uncovered underlying metabolic changes that regulate how immune cells react to COVID-19. These findings are associated with COVID-19 severity and may predict patient survival. The work was published in the journal Nature Biotechnology.
ISB Co-founder Dr. Lee Hood hosted a fireside chat with NIH Director Dr. Francis Collins. The renowned scientists talked about their early careers and long friendship, the challenge of COVID-19, the preceding scientific work that led to the fast development of COVID vaccines, and much more.
ISB researchers and their collaborators looked at the electronic health records of nearly 630,000 patients who were tested for SARS-CoV-2, and found stark disparities in COVID-19 outcomes — odds of infection, hospitalization, and in-hospital mortality — between White and non-White minority racial and ethnic groups.
The gut microbiome is an integral component of the body, but its importance in the human aging process is unclear. ISB researchers and their collaborators have identified distinct signatures in the gut microbiome that are associated with either healthy or unhealthy aging trajectories, which in turn predict survival in a population of older individuals.
NIAID Director Dr. Anthony Fauci sat down for a conversation with ISB’s Dr. Lee Hood. The renowned scientists spoke about the importance of basic research, the extraordinary speed of COVID research, the efficacy of mRNA vaccines on COVID-19, lessons learned from the COVID-19 pandemic, and much more.
ISB researchers and their collaborators are looking beyond the one-drug, one-solution approach that has thus far failed in Alzheimer’s disease research. Instead, they are focusing on other promising research avenues, such as the possible role of the gut microbiome in dementia.
ISB researchers examined the associations between the gut microbiomes of about 3,400 people and roughly 150 host characteristics. The team looked at diet, medication use, clinical blood markers, and other lifestyle and clinical factors, and found evidence that variations of the gut microbiome are associated with health and disease.
By analyzing blood plasma samples taken at several time points, ISB researchers have identified specific proteins that persistently presented as outliers and signaled metastatic cancer well before patients were diagnosed. The findings were published in the journal Scientific Reports.
Diseases develop gradually over years, sometimes decades, before symptoms appear, and are due to malfunctioning physiological processes brought about by our genes and environment. In research published in the journal Proceedings of the National Academy of Sciences (PNAS), ISB researchers have shown how an individual’s genetic risk for disease is often reflected in their blood.
There is a dichotomy between Bacteroides- and Prevotella-dominated guts — two common gut bacterial genera — and there is a significant barrier when it comes to transitioning from one to the other.
In the cellular process of differentiation, information about the concentrations of an important class of proteins residing in a cell’s nucleus has been lacking, a missing link needed for scientists to fully understand how the process works. ISB researchers have quantified this important class of proteins that play a key role in the formation of red blood cells.
Researchers at ISB harnessed deep molecular and physiological information to determine an individual’s biological age, which they found was reflective of overall health compared to chronological age. The findings were published in the Journals of Gerontology: Series A.
Predicting the alpha diversity of an individual’s gut microbiome is possible by examining metabolites in the blood. The robust relationship between host metabolome and gut microbiome diversity opens the door for a fast, cheap and reliable blood test to identify individuals with low gut diversity.
ISB, Integrated Diagnostics and Sera Prognostics just announced a paper entitled, “The building blocks of successful translation of proteomics to the clinic,” by Leroy Hood and colleagues published online in Current Opinion in Biotechnology.
Institute for Systems Biology (ISB) is among several organizations conducting a clinical trial testing how health coaching affects the cognitive function of patients with early-stage Alzheimer’s disease and analyzing longitudinal, multi-omic data to explore transitions in cognitive function over time.
Institute for Systems Biology and Arivale “Pioneer 100 Study” Establishes Foundation for New Industry of Scientific Wellness. Personal, dense, dynamic data clouds enable novel insights into mechanisms of wellness and disease, new approaches to biomarker discovery, and the empowerment of individuals to enhance their own health.
NIH Research Matters published an article on our tuberculosis paper. “The incredibly large number of possible drug combinations taken together with the difficulty of growing Mtb in the laboratory make discovery of effective combination therapy extremely challenging,” Dr. Nitin Baliga says. “We hope that our systems-based strategy will accelerate TB drug discovery by helping researchers prioritize combinations that are more likely to be effective.” READ THE ARTICLE